Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanoma

A Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group.

The trial also found that a response measured by circulating tumor DNA (ctDNA) predicted benefit, providing a biomarker that goes beyond standard imaging and progression assessments.

These results suggest tebentafusp could become a new standard of care for this rare and aggressive cancer, though additional follow‑up and real‑world evidence will be important to confirm its impact.